Home
Jacobio Pharma

Jacobio Pharma Market Share Analysis for June 2026

加科思药业(1167.hk)致力于为患者提供突破性治疗方案。公司在研项目围绕kras、肿瘤免疫、肿瘤代谢、p53、rb、myc六大肿瘤信号通路布局，核心项目以全球前三为目标。公司的愿景是与合作伙伴携手共进，成为全球认可的药物研发领导者。加科思的实验室坐落于中国北京、上海和美国波士顿，拥有诱导变构药物发现平台和iadc药物研发平台。

Industry: N/A

Domainjacobiopharma.com

Year Founded2015

Employees201 - 500

Annual Revenue$50M - $75M

Jacobio Pharma

Jacobio Pharma (including company regionals)

jacobiopharma.com

See more website traffic and engagement information

Jacobio Pharma Revenue up to June 2026 is 50M - 75M

revenue generated by Jacobio Pharma top domains

Jacobio Pharma top domains revenue over 3 years

Revenue for Jacobio Pharma top domains

jacobiopharma.com50M - 75M

See more with Sales Intelligence

Total visits to Jacobio Pharma's top domains

Understand Jacobio Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

jacobiopharma.com2.7K

See more with Sales Intelligence

Avg. visit duration in Jacobio Pharma's top domains

Analyze Jacobio Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

jacobiopharma.com00:00:21

See more with Sales Intelligence

Avg. pageviews on Jacobio Pharma's top domains

See how Jacobio Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

jacobiopharma.com2.18

See more with Sales Intelligence

Jacobio Pharma top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Jacobio Pharma

These are the website technologies, by industry, used by Jacobio Pharma top domains

Conversion & Analytics (3)

Google Analytics

Social (2)

AddThis

Widget (2)

Lockerz Share

Advertising (1)

Baidu Ads

More Technologies

6

See all

News & Signals from Jacobio Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsJacobiopharma invests into HebeCell Corp.Jacobio previously made a strategic investment in HebeCell and has collaborated with the company on the development of next-generation PSC-derived NK cell therapies.

NewsJacobiopharma hires Yan Chen as Vice President of CMC.Jacobio Pharma appoints Dr. Yan Chen as Vice President of CMC to accelerate development of its small molecule and xADC platforms.

NewsJacobiopharma partnered with Allist Pharmaceuticals Co., Ltd. on Jul 1st '24.Jacobio had already teamed up with Allist Pharmaceuticals (688578.SH) in 2024 to accelerate the drug's market launch, with the partner taking responsibility for China sales.